Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy

NCT ID: NCT04533958

Last Updated: 2025-05-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-28

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prostate cancer is the first cancer in men. The treatment of metastatic prostate cancer with chemotherapy is based on the intravenous administration of docetaxel chemotherapy. Symptoms of anticipatory nausea, linked to anxiety caused by the treatment, may occur. Hypnosis is already used to treat the anxiety of people with cancer and can help treat the symtoms of nausea and vomiting of women with breast cancer.

The purpose of the study is to evaluate the effect of medical hypnosis in virtual reality on the anxiety of patients with metastatic prostate cancer receiving Docetaxel chemotherapy treatment in comparison with a control group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After verifying the patient's eligibility criteria and obtaining the signed informed consent form, the patient is randomized to the arm receiving hypnosis in virtual reality or to the control arm. The study ends after the 12 courses of docetaxel or premature termination of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HypnoVR Arm

During each Docetaxel infusion, patients benefit from a 20-minute session of medical hypnosis in virtual reality.

Group Type EXPERIMENTAL

HYPNO VR® device

Intervention Type DEVICE

The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.

Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.

After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the "return" and exit hypnosis phase under the supervision of the nursing staff.

Control Arm

Patients receive the docetaxel infusions under standard conditions (no medical hypnosis in virtual reality intervention)

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HYPNO VR® device

The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.

Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.

After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the "return" and exit hypnosis phase under the supervision of the nursing staff.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man aged ≥ 18 years
* Histologically proven metastatic prostate adenocarcinoma,
* Patient undergoing chemotherapy according to the following conventional scheme: 12 courses of Docetaxel every two weeks
* Patient who signed their informed consent
* Patient benefiting from social security coverage
* Patient treated and followed in the center for the duration of the study (6 months maximum).

Exclusion Criteria

* Patient participating in another clinical trial on an experimental molecule
* Patient who received previous chemotherapy
* Patient unable to submit to protocol monitoring for psychological, social, family or geographic reasons
* Patient deprived of their liberty or under guardianship
* Patient with underlying or concomitant pathology incompatible with inclusion in the trial, whether psychiatric or somatic
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Saint-Gregoire Private Hospital Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xavier ARTIGNAN, MD

Role: PRINCIPAL_INVESTIGATOR

CHP Saint Grégoire

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinique Pasteur-Lanroze

Brest, , France

Site Status RECRUITING

CHP Saint-Grégoire

Saint-Grégoire, , France

Site Status RECRUITING

Clinique de la Côte d'Emeraude

St-Malo, , France

Site Status RECRUITING

Hospital Lusiadas Amadora

Amadora, , Portugal

Site Status RECRUITING

Hospital Lusiadas Lisboa

Lisbon, , Portugal

Site Status RECRUITING

Hospital Lusiadas Porto

Porto, , Portugal

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France Portugal

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

BELLEC-FAGOT

Role: CONTACT

0637110376

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ali Hasbini

Role: primary

+33 2 98 31 33 30

BELLEC-FAGOT

Role: primary

06.37.11.03.76

Flora Ahrweiller

Role: primary

+33 2 23 52 20 20

Sergio Barroso

Role: primary

+351 21 499 9380

Paulo Cortes

Role: primary

+351 21 770 4040

Miguel Barbosa

Role: primary

+351 22 605 6450

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-A03336-51

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.